Barrett, J. Carl

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

Thress, K. S., Paweletz, C. P., Felip, E., Cho, B. C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., et al. (2015) · Nature Medicine

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 1,589

Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins

Michishita, E., Park, J. Y., Burneskis, J. M., Barrett, J. C., & Horikawa, I. (2005) · Molecular Biology of the Cell

Sirtuins and Resveratrol in MedicineGenetics, Aging, and Longevity in Model Organisms

Cited by 1,364

SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin

Michishita, E., McCord, R. A., Berber, E., Kioi, M., Padilla-Nash, H., Damian, M., Cheung, P., Kusumoto, R., Kawahara, T. L. A., Barrett, J. C., et al. (2008) · Nature

Sirtuins and Resveratrol in MedicineTelomeres, Telomerase, and Senescence

Cited by 1,111

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer

Oxnard, G. R., Thress, K. S., Alden, R. S., Lawrance, R., Paweletz, C. P., Cantarini, M., Yang, J. C.-H., Barrett, J. C., & Jänne, P. A. (2016) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 850

Senescing human cells and ageing mice accumulate DNA lesions with unrepairable double-strand breaks

Sedelnikova, O. A., Horikawa, I., Zimonjic, D. B., Popescu, N. C., Bonner, W. M., & Barrett, J. C. (2004) · Nature Cell Biology

Telomeres, Telomerase, and SenescenceDNA Repair Mechanisms

Cited by 790

Increased insulin sensitivity and hypoglycaemia in mice lacking the p85α subunit of phosphoinositide 3–kinase

Terauchi, Y., Tsuji, Y., Satoh, S., Minoura, H., Murakami, K., Okuno, A., Inukai, K., Asano, T., Kaburagi, Y., Ueki, K., et al. (1999) · Nature Genetics

Metabolism, Diabetes, and CancerPI3K/AKT/mTOR signaling in cancer

Cited by 399

Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA

Abbosh, C., Frankell, A. M., Harrison, T., Kisistok, J., Garnett, A., Johnson, L., Veeriah, S., Moreau, M., Chesh, A., Chaunzwa, T. L., et al. (2023) · Nature

Cancer Genomics and DiagnosticsLung Cancer Diagnosis and Treatment

Cited by 382

Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study

Ramalingam, S. S., Cheng, Y., Zhou, C., Ohe, Y., Imamura, F., Cho, B. C., Lin, M.-C., Majem, M., Shah, R., Rukazenkov, Y., et al. (2018) · Annals of Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 366

Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade

Zhang, Q., Luo, J., Wu, S., Si, H., Gao, C., Xu, W., Abdullah, S. E., Higgs, B. W., Dennis, P. A., van der Heijden, M. S., et al. (2020) · Cancer Discovery

Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

Cited by 348

Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study

Papadimitrakopoulou, V. A., Wu, Y.-L., Han, J.-Y., Ahn, M.-J., Ramalingam, S. S., John, T., Okamoto, I., Yang, J. C.-H., Bulusu, K. C., Laus, G., et al. (2018) · Annals of Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 252

Gene Expression Profiles Associated with Response to Chemotherapy in Epithelial Ovarian Cancers

Jazaeri, A. A., Awtrey, C. S., Chandramouli, G. V. R., Chuang, Y. E., Khan, J., Sotiriou, C., Aprelikova, O., Yee, C. J., Zorn, K. K., Birrer, M. J., et al. (2005) · Clinical Cancer Research

Ovarian cancer diagnosis and treatmentGene expression and cancer classification

Cited by 192

Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based ctDNA Assays: A Joint Consensus Recommendation of the BloodPAC’s Analytical Variables Working Group

Godsey, J. H., Silvestro, A., Barrett, J. C., Bramlett, K., Chudova, D., Deras, I., Dickey, J., Hicks, J., Johann, D. J., Leary, R., et al. (2020) · Clinical Chemistry

Cancer Genomics and DiagnosticsClinical Laboratory Practices and Quality Control

Cited by 104

Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown

Pore, N., Wu, S., Standifer, N., Jure-Kunkel, M., de los Reyes, M., Shrestha, Y., Halpin, R., Rothstein, R., Mulgrew, K., Blackmore, S., et al. (2021) · Cancer Discovery

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 88